

CASE STUDIES

The Histopathology CRO

2026



CASE STUDY |

"StageBio delivered rapid, expert pathology validation with excellent responsiveness, giving us confidence in advancing our programmes."



The Challenge

- Fast-moving discovery engine generating first-in-class targets
- Need for established IHC protocols for novel biomarkers
- Urgent requirement to assess tissue selectivity and safety risk
- High confidence data needed for milestone decisions

StageBio's Approach

- Custom IHC assay development for novel targets
- Broad tumour and normal tissue profiling
- Board-certified pathology review
- Digital slide sharing for rapid scientific alignment
- Accelerated, milestone-driven reporting

Outcomes & Impact

- Faster candidate prioritisation
- Early off-tumour risk identification
- De-risked & IND-enabling confidence built on tissue evidence
- Seamless extension of DISCO's R&D capability
- Accelerated decision making & early risk mitigation

"StageBio has been an excellent partner in the validation of our novel discovery targets. Their combination of operational responsiveness and high-level pathology expertise is a differentiator in the industry. The speed and clarity of their communication provided our team with confidence that our programs were being supported by industry grade standards."

Dr. Roopika Menon | VP Tissue Analytics | DISCO Pharmaceuticals

"Supporting DISCO's innovative approach to target discovery required us to be as agile as they are. Our team thrived on the fast-paced nature of this project, using our IHC expertise to turn complex proteomic data into clear, actionable histological results. It's a perfect example of how rapid communication and expert pathology input can move a pipeline forward."

Dr Thomas Lemarchand, DVM, DEV-AP PhD, DECVP | Director of Pathology | StageBio

